NCT05413668View on ClinicalTrials.gov

First in Human Study of RVP-001, a New Manganese Based MRI Contrast Agent

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 18, 2022

Primary Completion Date

July 22, 2022

Study Completion Date

August 22, 2022

Conditions
Healthy
Interventions
DRUG

RVP-001

Intravenous administration of RVP-001

DRUG

Placebo

Intravenous administration of saline placebo

Trial Locations (1)

33126

Quotient Sciences, Miami

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Quotient Sciences

INDUSTRY

lead

Reveal Pharmaceuticals Inc.

INDUSTRY